MX351307B - Método para producir el compuesto sulfonilamidina. - Google Patents

Método para producir el compuesto sulfonilamidina.

Info

Publication number
MX351307B
MX351307B MX2015002961A MX2015002961A MX351307B MX 351307 B MX351307 B MX 351307B MX 2015002961 A MX2015002961 A MX 2015002961A MX 2015002961 A MX2015002961 A MX 2015002961A MX 351307 B MX351307 B MX 351307B
Authority
MX
Mexico
Prior art keywords
amidine compound
product
target compound
producing
production method
Prior art date
Application number
MX2015002961A
Other languages
English (en)
Other versions
MX2015002961A (es
Inventor
Yoshino Toshitaka
Kikuchi Takashi
Yoshida Shinya
Nakamura Atsushi
Akiba Takahiro
Sato Kiichi
Nakagawa Shuichi
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of MX2015002961A publication Critical patent/MX2015002961A/es
Publication of MX351307B publication Critical patent/MX351307B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D309/06—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • C07D309/12—Oxygen atoms only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Pyrane Compounds (AREA)

Abstract

Se proporcionan: un método para producir un compuesto sulfonilamidina, que tiene un excelente antagonismo del receptor de hormona liberadora de gonadotropina y es útil como un agente terapéutico para enfermedades dependientes de gonadotropina (por ejemplo, cáncer de próstata, cáncer de mama, endometriosis, fibroides uterinos, hiperplasia prostática, o similares) o una sal del mismo, y un intermediario de síntesis útil en el método de producción. El método de producción de acuerdo con la presente invención, mediante el cual se inhibe la formación de un subproducto, donde dicho subproducto difícilmente se elimina a menos que se conduzca la purificación de columna, y se inhibe la racemización de un compuesto objetivo y por lo tanto se obtiene el compuesto objetivo a una alta pureza, es adecuado para la producción industrial.
MX2015002961A 2012-09-07 2013-09-06 Método para producir el compuesto sulfonilamidina. MX351307B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012197914 2012-09-07
PCT/JP2013/074076 WO2014038663A1 (ja) 2012-09-07 2013-09-06 スルホニルアミジン化合物の製造法

Publications (2)

Publication Number Publication Date
MX2015002961A MX2015002961A (es) 2015-09-24
MX351307B true MX351307B (es) 2017-10-10

Family

ID=50237268

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015002961A MX351307B (es) 2012-09-07 2013-09-06 Método para producir el compuesto sulfonilamidina.

Country Status (8)

Country Link
US (1) US9527818B2 (es)
EP (1) EP2894152A4 (es)
JP (1) JP6222094B2 (es)
KR (1) KR20150048762A (es)
CN (1) CN104603114B (es)
CA (1) CA2883126A1 (es)
MX (1) MX351307B (es)
WO (1) WO2014038663A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201613579A (en) 2014-06-24 2016-04-16 Astellas Pharma Inc Pharmaceutical composition for oral administration
KR20200027481A (ko) 2017-06-05 2020-03-12 옵스에파 에스에이 자궁내막증의 치료를 위한 고나도트로핀 방출호르몬 길항제 투약요법

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06014131A (es) 2004-06-04 2007-03-07 Astellas Pharma Inc Derivado de propano-1,3-diona o su sal.
KR101046039B1 (ko) 2005-03-31 2011-07-01 아스텔라스세이야쿠 가부시키가이샤 프로판-1,3-디온 유도체 또는 그의 염
ZA200708264B (en) * 2005-03-31 2008-12-31 Astellas Pharma Inc Propane-1,3-dione derivative or salt thereof

Also Published As

Publication number Publication date
CA2883126A1 (en) 2014-03-13
CN104603114A (zh) 2015-05-06
JP6222094B2 (ja) 2017-11-01
EP2894152A1 (en) 2015-07-15
EP2894152A4 (en) 2016-03-09
WO2014038663A1 (ja) 2014-03-13
KR20150048762A (ko) 2015-05-07
US20150259299A1 (en) 2015-09-17
JPWO2014038663A1 (ja) 2016-08-12
CN104603114B (zh) 2017-06-20
MX2015002961A (es) 2015-09-24
US9527818B2 (en) 2016-12-27

Similar Documents

Publication Publication Date Title
CY1119731T1 (el) Διαδικασια για την παρασκευη παραγωγων χολικου οξεος
PH12015502839A1 (en) Antiviral compounds
NZ701947A (en) Processes to produce certain 2-(pyridine-3-yl)thiazoles
EA033513B1 (ru) Способы получения хинолиновых соединений и фармацевтических композиций, содержащих такие соединения
CO7141403A2 (es) Procesos para producir ciertos 2 (piridin 3 il)tiazoles
NZ705827A (en) Method of synthesizing thyroid hormone analogs and polymorphs thereof
TW201240990A (en) Antiviral compounds
MX2011012058A (es) Compuestos antivirales.
MX340573B (es) Proceso para la fabricacion de compuestos farmaceuticamente activos.
MX364930B (es) Proceso de producción a gran escala de dimesilato de 1-[(2-bromofenil]sulfonil]-5-metoxi-3-[(4-metil-1-piperazinil)met il]-1h-indol monohidratado.
MX2016008259A (es) Metodo de proceso para inhibidores de fosfatidilinositol 3-cinasa.
MX2023005704A (es) Metodo para manufacturar compuesto novedoso que contiene nitrogeno o sal del mismo e intermediario de manufacturacion del compuesto novedoso que contiene nitrogeno o sal del mismo.
AR090566A1 (es) Proceso para la produccion de inhibidores de crr
PH12015500794A1 (en) Monohydrate crystal of fimasartan potassium salt, method for preparing same, and pharmacological composition comprising same
IN2014DN09053A (es)
UA116640C2 (uk) Спосіб виробництва танталових сплавів
UY31577A1 (es) Proceso para la preparacion de 6-sustituido-1-(2h)-isoquinolinonas
BR112012013582A2 (pt) processo para síntese de intermediários úteis para a produção de compostos de indazol e azaindazol substituídos
PH12015501952B1 (en) Improved preparation method for high-yield production of physiologically active polypeptide conjugate
MX351307B (es) Método para producir el compuesto sulfonilamidina.
ECSP13012548A (es) Inhibidores de oxadiazol de la producción de leucotrienos.
BR112016006865A2 (pt) berberinas substituídas e suas sínteses
CO7141402A2 (es) Procesos para producir ciertos 2 (piridin 3 il)tiazoles
MX337997B (es) Nuevo procedimiento de sintesis de la ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable.
FR2980334B1 (fr) Renforecement azote d'engrais foliaires therapeutiques

Legal Events

Date Code Title Description
FG Grant or registration